🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesHas anyone dealt with insulin sensitivity vs insulin secretion? Page 2

Has anyone dealt with insulin sensitivity vs insulin secretion?

MikeKY_noInsulin Tue, Nov 25, 2025 at 9:06 PM 9 replies 1,005 viewsPage 2 of 2
Dr.SleepRoch
Senior Member
1,123
5,678
Apr 2024
Rochester, MN
Nov 26, 2025 at 5:47 PM#6
mike.trainer_LA said:
Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 41% to 21%.

PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

After 9 months: periods became regular for the first time in ever, testosterone levels normalized, acne cleared significantly, and — unexpectedly — my hormonal symptoms have almost completely resolved.

GLP-1 agonists address the insulin resistance at the root of PCOS. For PCOS patients, this isn't "just" a weight loss drug — it's treating our underlying metabolic dysfunction.

1 21sarah_TO
Reply Quote Save Share Report
HPLC_Greg
Senior Member
1,890
8,901
Feb 2024
Research Triangle, NC
Nov 27, 2025 at 2:00 AM#7
MikeKY_noInsulin said:
Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)1191019185
Insulin (fasting)2515115
HOMA-IR5.54.01.91.3
Uric Acid8.76.95.85.0

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 5.5 to near 1.0 is a metabolic transformation.

Last edited: Nov 27, 2025 at 8:00 AM
50 20JenPlateau, SallyK_inj, CryptoCarl and 47 others
Reply Quote Save Share Report
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
Nov 27, 2025 at 10:14 AM#8
Dr.SleepRoch said:
PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 5.5 (insulin resistant) → Current = 1.5 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

49 19JennaRN, LabKate, kate.chem and 46 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
jason_sac26
New Member
34
123
Jan 2026
Sacramento, CA
Nov 27, 2025 at 6:28 PM#9

A narrower follow-up, since the general answer is now clear:

What would you measure differently if you were starting again?

48 18maya_sedona, stefan_berlin, Dr.EM_Chicago and 45 others
Reply Quote Save Share Report
MikeKY_noInsulin
Member
267
1,234
Oct 2024
Louisville, KY
Nov 29, 2025 at 9:59 AM#10
MASHdoc_SA said:
Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking: HOMA-IR = (fasting…

Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction than glucose or A1C.

My fasting insulin: 31 → 15 → 5 uIU/mL over 9 months. Target is <7. By the time your fasting glucose is elevated, your insulin has been elevated for YEARS trying to compensate.

Ask your doctor to include fasting insulin in your bloodwork panel. It's cheap (~$20) and incredibly informative.

16 14bbq_ray_KC, oliver_london, tane_welly and 13 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register